Photo via CNBC Business
CVS Health announced it will restore coverage of Zepbound, Novo Nordisk's popular GLP-1 receptor agonist for weight management, effective October 1. The pharmacy and health benefits giant will simultaneously begin covering Eli Lilly's newly approved Foundayo pill starting June 1, expanding patient access to obesity treatment options across its insured populations.
The dual announcement signals a significant shift in how major pharmacy benefit managers are approaching obesity medications. According to the CVS announcement, both drugs will be made available through the company's pharmacy benefit management plans, potentially affecting millions of patients nationwide—including those in the Nashville region covered by CVS-administered plans.
For Nashville-area employers and employees, this expansion means broader access to medications that have shown clinical effectiveness in weight management and metabolic health. Local businesses that self-insure or partner with CVS for employee health benefits may see these treatments become more accessible to their workforce, while individual consumers covered under CVS plans will have new options previously unavailable to them.
The addition of these GLP-1 medications to CVS's formularies reflects growing recognition of obesity as a treatable medical condition in mainstream healthcare. As demand for these medications continues to rise nationally, pharmacy benefit managers like CVS are adjusting their coverage policies, potentially reshaping how obesity treatment is delivered and funded in Tennessee's healthcare marketplace.
